Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

BACKGROUND. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. Efficacy of afatinib in EGFR tyrosine kinase inhibitor-naïve (TKI-naïv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Heigener, David F., Schumann, Christian, Sebastian, Martin, Sadjadian, Parvis, Stehle, Ingo, Märten, Angela, Lüers, Anne, Griesinger, Frank, Scheffler, Matthias
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591955/
https://ncbi.nlm.nih.gov/pubmed/26354527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0073
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados